MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Comparative Study of limits of stability Improvements in Young-Onset vs. Late-Onset Parkinson’s Disease Following One-Year Biofeedback Balance Training

    MYA. Amine, YM. Mahmoud, FAR. Mehana, MAY. Hosny (Cairo, Egypt)

    Objective: This study aims to assess the impact of balance training and early detection of stability limits in PD on the responsiveness of young and…
  • 2025 International Congress

    Efficacy and Safety of IPX203 and Levodopa-Carbidopa Intestinal Gel (LCIG) Compared to Immediate-Release Carbidopa-Levodopa in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    M. Mustafa, A. Abunamoos, Y. Aljazi, F. Alnajjar, A. Sa’D, M. Alghaniem, K. Abuhananeh (Amman, Jordan)

    Objective: To conduct the efficacy and safety of IPX203, an extended-release carbidopa-levodopa formulation, and LCIG, a continuous levodopa infusion, compared to Immediate-Release Carbidopa-Levodopa (IR CD-LD)…
  • 2025 International Congress

    Targeting inflammation and autophagy: a dual-inhibition strategy to reduce α-synuclein pathology in GBA1-associated Parkinson’s disease

    T. Usenko, A. Bezrukova, K. Basharova, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)

    Objective: To assess the effects of combined inhibition of mTOR (autophagy regulator) and STING (inflammation regulator) on α-synuclein phosphorylation, tyrosine hydroxylase expression, and lysosphingolipid levels in…
  • 2025 International Congress

    A Phase 1b Study to Investigate Safety and Tolerability of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease

    K. Holmström, K. Jääskeläinen, N. Kulesskaya, J. Koskinen, R. Holmnäs, A. Vuolanto, A. Domanska, M. Engström, P. Vainio, M. Scheinin, C. Videbaek, A. Tornio, Z. Lovro, F. Scheperjans, J. Rinne, H. Huttunen (Espoo, Finland)

    Objective: To investigate safety and tolerability of repeated subcutaneous (s.c.) doses of HER-096 in subjects with Parkinson’s disease. Background: HER-096 is a retro-inverso isomerized peptide…
  • 2025 International Congress

    Remote Deep Brain Stimulation Programming for Parkinson’s Disease: A Multicenter Randomized Non-Inferiority Trial

    J. Shaik, V. Zentsch, C. Buhmann, T. Kinfe, M. Regensburger, J. Rumpf, A. Schnitzler, G. Höglinger, J. Mehrkens, T. Koeglsperger (Muenster, Germany)

    Objective: To evaluate the effectiveness and safety of remote vs. on-site DBS programming in Parkinson’s disease patients with STN-DBS. Background: Deep brain stimulation (DBS) is…
  • 2025 International Congress

    Exploring minzasolmin effect on digital measures captured by the Verily Study Watch in a subset of the ORCHESTRA trial participants

    B. Bloem, V. Hinson, E. Goikoetxea, L. Gaetano, K. Ray, F. Ambrosetti, KC. Ho, M. Key Prato, A. Pethe, V. Ticcinelli, J. Trzebinski, S. Warma, A. Khanna, Z. Ali (Nijmegen, Netherlands)

    Objective: To investigate the progression over time and the effect of minzasolmin on digital outcomes collected in ORCHESTRA (NCT04658186). Background: Minzasolmin is an oral small…
  • 2025 International Congress

    The cerebellum encodes dynamic motor frequencies for volitional movements

    YM. Wang, CW. Liu, WC. Liu, MK. Pan (Taipei, Taiwan)

    Objective: Investigate how the cerebellum computes and regulates motor precision during daily movements Background: Motor coordination, ensuring movement precision and reliability, is governed by the…
  • 2025 International Congress

    Longitudinal Remote Monitoring with Wearable Technology in Parkinson Disease: Initiation of A Dyskinesia Insight Network Observational Study

    R. Gilron, A. Hare, M. Grall, P. Qin, S. Isaacson (San Francsico, USA)

    Objective: Evaluate the utility of wearable digital health technology for identifying and characterizing levodopa-induced dyskinesia in real-world settings. Background: Patients with Parkinson disease (PwP) frequently…
  • 2025 International Congress

    Trends on recruitment and retention in Parkinson’s Disease modification trials

    D. Hengartner, R. Palacio, J. Garinger, A. Lysandropoulos (Durham, USA)

    Objective: To identify the most common causes of participant’s screen failure (SF) and drop-out (DO) in Phase 2 and 3 Disease Modification Therapy (DMT) trials…
  • 2025 International Congress

    Enhancing Sleep in Parkinson’s Disease: A Retrospective Study on Group CBT-I

    N. Hellmers, A. Weiss, D. Zhang, P. Glovinsky, D. Barone, A. Yoo, H. Ooi, H. Sarva (New York, USA)

    Objective: Weill Cornell Sleep Center and our movement disorder team developed a treatment program for individuals with Parkinson’s Disease (PD) with sleep disturbances. The goal…
  • « Previous Page
  • 1
  • …
  • 271
  • 272
  • 273
  • 274
  • 275
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley